Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors
- PMID: 16452178
- DOI: 10.1158/0008-5472.CAN-05-3497
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors
Abstract
Oncolytic adenoviruses represent an innovative approach to cancer therapy. These vectors are typically evaluated in immunodeficient mice with human xenograft tumors. However, in addition to being immunodeficient, this model is limited because normal and cancerous mouse tissues are poorly permissive for human adenovirus replication. This prompted us to search for a model that more accurately reflects the use of oncolytic adenoviruses in cancer patients. To this end, we developed a novel Syrian hamster model that is both immunocompetent and replication-permissive. We found that human adenovirus replicates well in Syrian hamster cell lines and confirmed replication in the lungs. Oncolytic adenovirus injection showed efficacy in three different hamster tumor models. Furthermore, i.t. oncolytic adenovirus injection resulted in suppression of primary and metastatic lesions, i.t. replication and necrosis, vector entrance into the bloodstream, replication in the liver and lungs, and anti-adenovirus antibody induction. Our findings show that the Syrian hamster is a promising immunocompetent model that is permissive to human adenovirus replication in tumors as well as normal tissues. Therefore, the Syrian hamster model may become a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and efficacy can be evaluated.
Similar articles
-
Syrian hamster tumor model to study oncolytic Ad5-based vectors.Methods Mol Biol. 2012;797:53-63. doi: 10.1007/978-1-61779-340-0_4. Methods Mol Biol. 2012. PMID: 21948468
-
Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.Methods Mol Med. 2007;130:169-83. doi: 10.1385/1-59745-166-5:169. Methods Mol Med. 2007. PMID: 17401172
-
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.J Gene Med. 2010 May;12(5):435-45. doi: 10.1002/jgm.1453. J Gene Med. 2010. PMID: 20440754
-
Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.Adv Cancer Res. 2012;115:69-92. doi: 10.1016/B978-0-12-398342-8.00003-3. Adv Cancer Res. 2012. PMID: 23021242 Review.
-
Replication-selective oncolytic viruses in the treatment of cancer.Cancer Gene Ther. 2005 Feb;12(2):141-61. doi: 10.1038/sj.cgt.7700771. Cancer Gene Ther. 2005. PMID: 15472714 Review.
Cited by
-
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018. doi: 10.1038/mtm.2016.18. eCollection 2016. Mol Ther Methods Clin Dev. 2016. PMID: 27088104 Free PMC article. Review.
-
Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.Virology. 2015 Nov;485:305-12. doi: 10.1016/j.virol.2015.07.024. Epub 2015 Aug 28. Virology. 2015. PMID: 26319212 Free PMC article.
-
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.Mol Ther Oncolytics. 2022 Sep 13;27:3-13. doi: 10.1016/j.omto.2022.09.003. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36212775 Free PMC article.
-
AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapy.Am J Cancer Res. 2022 Jul 15;12(7):3141-3147. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968324 Free PMC article.
-
Increasing the efficacy of oncolytic adenovirus vectors.Viruses. 2010 Sep;2(9):1844-1866. doi: 10.3390/v2091844. Epub 2010 Aug 27. Viruses. 2010. PMID: 21994711 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources